Key result
Doxorubicin upregulates stress and apoptosis pathways and elevates plasma SERPINA3 in breast cancer patients.
Why the study?
Doxorubicin is an effective chemotherapeutic agent, but its clinical utility is limited by cardiotoxicity.
Population
Five-week-old male mice and DOX-treated breast cancer patients
Comparison
Weekly DOX (4 mg/kg) vs saline injections for six weeks
Design
Preclinical multi-omics study with clinical biomarker validation
Follow-up
4 days and 6 weeks post-treatment
Authors
Loading...
SERPINA3 may flag early doxorubicin cardiotoxicity risk; leaves open biomarker utility pending prospective validation.
This integrated omics study delineates the molecular mechanisms of doxorubicin-induced cardiotoxicity, identifying SERPINA3 as a potential biomarker.
Dabour et al. (2026) studied Doxorubicin-induced cardiotoxicity. Doxorubicin vs. saline was evaluated on Differentially expressed genes and proteins. Doxorubicin treatment induced dynamic remodeling of cardiac signaling, upregulating p53 signaling and apoptosis pathways, and significantly elevating plasma SERPINA3 in breast cancer patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: